Zobrazeno 1 - 10 of 26 pro vyhledávání: '"W. Koetse"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
POS1023 LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC DISEASE: FINDINGS FROM INTEGRATED ANALYSES OF 17 CLINICAL TRIALS IN PSORIASIS AND 4 IN PSORIATIC ARTHRITIS
Autor: K. B. Gordon, A. Blauvelt, H. Bachelez, B. Kaplan, W. Koetse, L. Drogaris, R. Sinvhal, K. Papp
Publikováno v: Annals of the Rheumatic Diseases. 81:823.1-823
BackgroundRisankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in phase 2 and 3 clinical studies in patients with psoriatic disease.ObjectivesTo report long-term risankizumab safety in patients with psoriatic disease.MethodsR
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27641b3d3aa735b57d1ea3e4526e2e9b
https://doi.org/10.1136/annrheumdis-2022-eular.1185
Zobrazit plný text záznamu
3
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis
Autor: Sang-Heon Lee, Chul Soo Cho, Young-Eun Park, Eun Mi Koh, Soo Kon Lee, Sang Cheol Bae, Young Mo Kang, Hoon Suk Cha, Min Chan Park, Seung Cheol Shim, Shin-Seok Lee, W. Koetse, Chang Hee Suh, Jung Yoon Choe, Yeong Wook Song, Bin Yoo, C Arendt, Won Park
Publikováno v: The Korean Journal of Internal Medicine. 33:1224-1233
BACKGROUND/AIMS The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity. METHODS In this 24-week, phase 3, randomized, dou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45d7cc50290236e239f89c776f28752e
https://doi.org/10.3904/kjim.2016.213
Zobrazit plný text záznamu
4
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials
Autor: S. Bongardt, Guy Meno-Tetang, William A. Wegener, W. Koetse, Anthony Shock, Marga Oortgiesen, David M. Goldenberg, Xavier Mariette, Jacques-Eric Gottenberg, Gordana Kosutic, Valérie Devauchelle-Pensec, C. Galateanu, Simon J. Bowman, Hendrika Bootsma, Thomas Dörner, Caroline Gordon, Holger Bartz
Publikováno v: Arthritis & rheumatology
Arthritis & rheumatology, Wiley, 2018, ⟨10.1002/art.40425⟩
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & Rheumatology, 70(5), 763-773. Wiley
Objective. EMBODY 1 (ClinicalTrials.gov identifier: NCT01262365) and EMBODY 2 (ClinicalTrials.gov identifier: NCT01261793) investigated the efficacy and safety of epratuzumab, a CD22-targeted humanized monoclonal IgG antibody, in patients with system
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254e87d0618ca01c7ec9833dee2f7d4a
https://hal.archives-ouvertes.fr/hal-01706654
Zobrazit plný text záznamu
5
A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
Autor: W. Koetse, Ahmed Samad, Jeffrey M. Melin, L. Gervitz, Laura Gauer, Jeffrey R. Curtis, Melvin Churchill, Alan Kivitz, Yusuf Yazici
Publikováno v: Arthritis & Rheumatology. 67:3104-3112
Objective The aim of the Patient/Physician Reported Efficacy Determination In Clinical Practice Trial (PREDICT; ClinicalTrials identifier NCT01255761) was to compare the patient-reported Routine Assessment of Patient Index Data 3 (RAPID-3) instrument
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a14a9da7e512566d6854bad381d0fd8e
https://doi.org/10.1002/art.39322
Zobrazit plný text záznamu
6
Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
Autor: W. Koetse, F. Staelens, P. Bertin, M. Greenwald, B. Bennett, O. Davies, Daniel E. Furst, S. A. Shaikh, K. Luijtens
Publikováno v: Arthritis Care & Research
Objective To investigate clinical efficacy and safety of 2 certolizumab pegol (CZP) maintenance dosing regimens plus methotrexate (MTX) in active rheumatoid arthritis (RA) patients achieving the American College of Rheumatology 20% improvement criter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e8ca6ca640da2a316a90abd0781946
http://europepmc.org/articles/PMC4329409
Zobrazit plný text záznamu
7
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity : the CERTAIN double-blind, randomised, placebo-controlled trial
Autor: W. Koetse, Josef S Smolen, Wlodzimierz Samborski, Oana Purcaru, Gianfranco Ferraccioli, Francis Berenbaum, O. Davies, Paul Emery, Barbara Bennett, Harald Burkhardt
Publikováno v: Annals of the Rheumatic Diseases
Objectives This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with lo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a08b88ba610a96d205515933607b11bb
http://publikationen.ub.uni-frankfurt.de/files/32540/843.full.pdf
Zobrazit plný text záznamu
8
FRI0002 Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Cynomolgus Monkeys and in Patients with Systemic Lupus Erythematosus
Autor: L. Brackenbury, N. Williams, S. Bongardt, W. Koetse, C. Galateanu, Anthony Shock, C. Stach, A. Wolfreys, B. Kilgallen
Publikováno v: Annals of the Rheumatic Diseases. 74:420.2-420
Background Epratuzumab is a humanized monoclonal antibody (mAb) that targets the B cell-specific protein CD22 and is currently in Phase 3 clinical trials in patients (pts) with systemic lupus erythematosus (SLE). Epratuzumab is not a B cell depleting
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::004ddb7b51083fbbb2940c7163762e0f
https://doi.org/10.1136/annrheumdis-2015-eular.2255
Zobrazit plný text záznamu
9
FRI0004 Randomization to Patient-Reported RAPID3 versus Physician-Based CDAI Tools for Prediction of Treatment Response and Assessment of Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Results from the PREDICT Study
Autor: L. Gauer, A. Samad, Alan Kivitz, G. Coteur, L. Gervitz, Yusuf Yazici, J. Melin, Jeffrey R. Curtis, W. Koetse, Melvin Churchill
Publikováno v: Annals of the Rheumatic Diseases. 73:382.1-382
Background Guidelines support regular quantitative disease activity monitoring and early intervention in rheumatoid arthritis (RA), but there is no uniform agreement on the best measurement tool. 1,2 While physician-based tools like the Disease Activ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d3db43e08491d3c24308f46282cae98
https://doi.org/10.1136/annrheumdis-2014-eular.1674
Zobrazit plný text záznamu
10
THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
Autor: W. Koetse, Vibeke Strand, S. Bongardt, Caroline Gordon, Michelle Petri, R.A. Furie, C. Galateanu, Daniel J. Wallace
Publikováno v: Annals of the Rheumatic Diseases. 73:184.1-184
Background Epratuzumab is a monoclonal antibody that targets CD22 on B cells. In EMBLEM™ (dose-ranging Phase 2b study [NCT00624351]), and its open-label extension (OLE; SL0008 [NCT00660881]), epratuzumab produced sustained and clinically relevant i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29dd0571a593041b6a85a3d7032057b4
https://doi.org/10.1136/annrheumdis-2014-eular.1854
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje